Navigation Links
Southern Research Institute Names Vladimir Yamshchikov Director of Infectious Disease Research Department in Birmingham
Date:11/5/2007

BIRMINGHAM, Ala., Nov. 5 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery, drug and vaccine development, advanced engineering, environmental and energy production, today announced the appointment of Vladimir Yamshchikov, Ph.D. as director of its Infectious Disease Research Dept. in Birmingham.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071105/6371)

"Dr. Yamshchikov has an impressive combination of scientific, technical and regulatory expertise, with more than 20 years experience with research in molecular virology in BSL-3 and ABSL-3 laboratories," said William R. Waud, Ph.D., interim vice president of the Drug Development Division at Southern Research. "His intimate knowledge and experience working with infectious diseases and select agents will serve him well as he manages this growing area of research at Southern Research."

Prior to joining Southern Research, Dr. Yamshchikov was an associate professor in the Department of Molecular Biosciences at the University of Kansas. He is a member of the American Society for Virology and has published more than 35 peer-reviewed research papers. He received his Master's degree in Bioorganic Chemistry from Moscow State University in Moscow, Russia and his doctorate in Bioorganic Chemistry & Molecular Biology from the Institute of Bioorganic Chemistry in Novosibirsk, Russia.

Dr. Yamshchikov has extensive experience and training in handling emerging pathogens and select agents in both BSL-3 and ABSL-3 laboratories. He also has hands-on experience working with a variety of human and veterinary pathogens and viral vectors. He spent more than 10 years managing a CDC/USDA certified BSL-3 and ABSL-3 facility approved by the FBI to handle select agents.

Southern Research also operates an Infectious Disease Research Dept. in Frederick, Md., directed by Michael G. Murray, Ph.D. Last year, Southern Research's BSL-3 laboratory in Birmingham underwent a $1 million renovation that included adding bioaerosol capabilities and expanding Southern Research's ability to conduct GLP-compliant studies in high containment, and to evaluate and test new therapeutics and vaccines to protect the public against select agents and emerging infectious diseases. The BSL-3 contains more than 8,300 square feet of in vitro and in vivo space. It is registered with the Centers for Disease Control (CDC) and the U.S. Department of Agriculture (USDA) to work with both animal and human risk group Level 3 pathogens, including highly-pathogenic avian influenza (HPAi), West Nile, SARS viruses and Bacillus anthracis (anthrax).

About Southern Research Institute

Southern Research Institute is a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery, vaccine and drug development, advanced engineering, environmental research and energy production. To date, Southern Research has discovered six FDA-approved cancer drugs and discovered six additional drugs that are currently in late stage preclinical and early clinical trials. No other company or institution has brought six of its own cancer drug discoveries to market. For more information, please visit http://www.southernresearch.org.


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
2. USAID Assistant Administrator Hess Travels to Southern Africa
3. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
4. MIT Holding, Inc. signs partnership agreement with Georgia Southern University
5. Angel Flight West Recognizes Southern California Pilots at 24th Anniversary
6. Southern California Wildfires Continue to Threaten Residential Areas
7. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
8. VA Remains Open for Care for Southern California Vets
9. Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts
10. The Salvation Army Responds to Immediate Needs of Survivors and Relief Workers in Southern California Wildfires
11. CNA/NNOC Nurse Volunteers Deployed to Southern California Firestorm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
Breaking Medicine Technology: